Aker BioMarine has reported revenues of USD 56.9 million and adjusted EBITDA of USD 8.1 million for the first quarter of 2022. In addition, sales in the Ingredients segment were in line with last year, and sales in the Brands segment were up 32%. Furthermore, offshore production volume was all-time high at 20,809 tons in the quarter.
Matts Johansen, CEO of Aker BioMarine, confirmed that the company has delivered strong growth in their Brands segment and record-high harvesting of Antarctic krill. "We have also strengthened the Superba krill oil sales organization in all geographies. Also, we will execute on our sales pipeline throughout the year to deliver growth. We reiterate our financial targets for the full year 2022," he concluded.
Although there will be seasonal and operational variations from year to year, the company plans for average annual harvesting volumes of 55,000-60,000 tonnes. According to Aker BioMarine, the harvesting volume in 2022 has been 25,800 tons.
Aker BioMarine is a leading biotech innovator and Antarctic krill-harvesting company. It develops krill-derived products for pharma, consumer health, and wellness as well as animal nutrition. The company is the world's leading supplier of krill. It is the natural, powerful, and health-promoting source of nutrients from the pristine waters of Antarctica.
Aker BioMarine is listed on Oslo Stock Exchange (AKBM). More information is available at www.akerbiomarine.com.